Journal
PATHOGENS
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/pathogens10020211
Keywords
microbiota; microbiome; inflammatory bowel disease; pharmacotherapy
Categories
Funding
- Institute for Maternal and Child Health Burlo Garofolo, Trieste, Italy [RC 1/17, RC 10/19]
Ask authors/readers for more resources
There is a mutualistic relationship between the gut microbiota and the efficacy of pharmacological therapy in inflammatory bowel disease (IBD). The gut microbiota can influence treatment responses and drug metabolism, while drugs used in IBD treatment can also modulate the microbial composition. Understanding this relationship is crucial in predicting treatment responses and optimizing therapeutic outcomes.
A mutualistic relationship between the composition, function and activity of the gut microbiota (GM) and the host exists, and the alteration of GM, sometimes referred as dysbiosis, is involved in various immune-mediated diseases, including inflammatory bowel disease (IBD). Accumulating evidence suggests that the GM is able to influence the efficacy of the pharmacological therapy of IBD and to predict whether individuals will respond to treatment. Additionally, the drugs used to treat IBD can modualate the microbial composition. The review aims to investigate the impact of the GM on the pharmacological therapy of IBD and vice versa. The GM resulted in an increase or decrease in therapeutic responses to treatment, but also to biotransform drugs to toxic metabolites. In particular, the baseline GM composition can help to predict if patients will respond to the IBD treatment with biologic drugs. On the other hand, drugs can affect the GM by incrementing or reducing its diversity and richness. Therefore, the relationship between the GM and drugs used in the treatment of IBD can be either beneficial or disadvantageous.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available